Pass RAC-GS - Regulatory Affairs Certification (RAC) GlobalScope exam in just 24 HOURS! 100% REAL EXAM QUESTIONS ANSWERS RAC-GS - Regulatory Affairs Certification (RAC) Global Scope Buy Complete Questions Answers File from http://www.exams4sure.net/raps/rac-gs-exam-questions-dumps.html 100% Exam Passing Guarantee & Money Back Assurance Sample Questions Question No 1: The Food and Drug Administration Modernization Act (FDAMA) established two types of formal early collaboration meetings. Which of the following is one of those meetings? A. B. C. D. PDP meeting Agreement Meeting Pre-IDE meeting Type A meeting Answer: B Question No 2: A sponsor intends to submit a Special Protocol Assessment (SPA) request for a clinical trial that will form the primary basis of an efficacy claim in an NDA. Which of the following is TRUE? A. The sponsor should submit the SPA request within 30 days following the start of the trial to expedite FDA feedback B. An SPA provides an opportunity to focus on general drug development issues C. The SPA request will be handled as a request for a Type B meeting D. A sponsor can submit a revised protocol while the agency is reviewing an earlier version of the same protocol Answer: D Question No 3: Devices that are exempt from premarket notification are: A. B. C. D. All Class I devices Some Class I devices Most Class I devices and some Class II devices All Class I devices and some Class II devices Answer: C Question No 4: Your company wishes to seek approval of a combination of individually approved antihypertensive and anti-diabetic drugs. However, there is no Reference Listed Drug (RLD) for the proposed combination. Which of the following regulatory pathways is most applicable? A. 505(b)(2) B. 510(k) C. 505(b)(1) D. 505(j) Answer: A Question No 5: The following applies to autologous chondrocytes expanded in vitro for the repair of cartilage defects: A. Regulated under Section 351 of the Public Health Service Act and no premarket approval required B. Regulated under Section 351 of the Public Health Service Act and premarket approval required C. Regulated under Section 361 of the Public Health Service Act and no premarket approval required D. Regulated under Section 361 of the Public Health Service Act and premarket approval required Answer: B Question No 6: Which of the following is the best regulatory pathway for drugs containing similar active ingredients as a previously approved drug for a new indication? A. B. C. D. 505(j) ANDA 505(b)(1) NDA 505(b)(2) NDA 505 (d) Substantial Evidence of Effectiveness Answer: C Question No 7: In order to be approved by FDA, a generic drug must be therapeutically equivalent to the branded product with the exception of: A. B. C. D. Dosage Form Route of Administration Inactive Ingredient(s) Labeling Answer: C Question No 8: Your company is developing a New Chemical Entity (NCE) drug to treat Glioblastoma multiforme, which is the deadliest and most common form of malignant brain tumor. The compound team has designed a pivotal study protocol with a clinically meaningful and wellestablished primary endpoint. To increase the likelihood FDA will agree with the study design, which of the following regulatory strategies has to occur prior to initiating the pivotal study? A. Request Fast Track designation B. Request priority review C. Request approval under Subpart H, Accelerated Approval of New Drugs for Serious or Life Threatening Illness D. Request Special Protocol Assessment Answer: D Question No 9: Which federal law made it illegal for physicians being reimbursed by federally funded programs to prescribe or recommend that the patient use a particular manufacturer's medical products when the doctor receives payment from that manufacturer? A. B. C. D. Medicare and Medicaid Patient Protection Act of 1987 Food, Drug, and Cosmetic Act of 1938 (FD&C Act) Food and Drug Administration Modernization Act of 1997 (FDAMA) Food and Drug Administration Amendments Act of 2007 (FDAAA) Answer: A Question No 10: Company Z selected a proprietary name for its new molecular entity, currently in development. The NDA will be submitted in six months. All of the following are Relevant to the proprietary name EXCEPT: A. The request for proprietary name approval may be submitted with the NDA. B. The proprietary name submission package may be Submitted up to one month after NDA submission. C. The request for proprietary name approval may be submitted prior to the NDA. D. FDA will communicate to the applicant a tentative acceptance or non-acceptance of the proposed proprietary name submitted with the NDA within 90 days of the receipt of the complete submission. Answer: B Buy Complete Questions Answers File from PDF Version + Test Engine Software Version 90 Days Free Updates Service Valid for All Countries http://www.exams4sure.net/raps/rac-gs-exam-questions-dumps.html